Analysis of Real-World PD-L1 Testing and PD-L1 IHC 28-8 and 22C3 Assay Concordance in Patients with Breast Cancer

被引：0
|
作者：
Prince, Emily [1 ]
Pratt, James [2 ]
Novotny, James [2 ]
Chizhevsky, Vladislav [3 ]
Ragheb, Josette William [3 ]
Huron, David [2 ]
机构：
[1] Bristol Myers Squibb, Philadelphia, PA USA
[2] Bristol Myers Squibb, Princeton, NJ USA
[3] NeoGen Labs Inc, Aliso Viejo, CA USA
来源：
LABORATORY INVESTIGATION | 2020年 / 100卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
244
引用
收藏
页码：238 / 239
页数：2
相关论文
共 50 条
  • [41] High concordance of the PD-L1 22C3 antibody LDT protocol on BenchMark XT compared to the PD-L1 IHC 22C3 pharmDx kit for urothelial carcinoma (UC) and head and neck squamous cell carcinoma (HNSCC)
    Vainer, G.
    Neuman, T.
    Fellig, Y.
    Meir, K.
    Hirshoren, N.
    Gofrit, O.
    Huang, L.
    Juco, J.
    Bal, T.
    VIRCHOWS ARCHIV, 2019, 475 : S95 - S95
  • [42] Routine PD-L1 Immunohistochemistry Testing by 22C3 in a Canadian Reference Testing Center
    Albaqer, T.
    Santiago, R.
    Leung, Y.
    Pal, P.
    Khan, Z.
    Torlakovic, E.
    Cheung, C.
    Hwang, D.
    Tsao, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2003 - S2003
  • [43] PD-L1 (22C3) Expression in Primary and Recurrent Glioblastoma
    Arvanitis, Leonidas
    Chen, Hsiao-Wei
    Louie, Carrie
    D'Apuzzo, Massimo
    Gu, Dongqing
    Yew, Hooi
    Portnow, Jana
    Badie, Benham
    Pillai, Raju
    Aoun, Patricia
    Telatar, Milhan
    Afkhami, Michelle
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1600 - 1600
  • [44] PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays
    Grabenstetter, Anne
    Jungbluth, Achim A.
    Frosina, Denise
    Hoda, Raza
    Dos Anjos, Carlos H.
    Patil, Sujata
    Sevilimedu, Varadan
    Weigelt, Britta
    Reis-Filho, Jorge S.
    Zhang, Hong
    Traina, Tiffany
    Robson, Mark E.
    Brogi, Edi
    Wen, Hannah Y.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2021, 45 (09) : 1274 - 1281
  • [45] Interlaboratory-concordance of PD-L1 IHC for NSCLC
    Scheel, Andreas H.
    Banfer, Gudrun
    Baretton, Gustavo Bruno
    Dietel, Manfred
    Diezko, Rolf
    Henkel, Thomas
    Heukamp, Lukas C.
    Jasani, Bharat
    Johrens, Korinna
    Kirchner, Thomas
    Petersen, Iver
    Reu, Simone
    Schildhaus, Hans-Ulrich
    Schirmacher, Peter
    Tiemann, Markus
    Warth, Arne
    Weichert, Wilko
    Wolf, Juergen
    Ruschoff, Josef
    Buettner, Reinhard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] PD-L1 (22C3) Expression in Primary and Recurrent Glioblastoma
    Arvanitis, Leonidas
    Chen, Hsiao-Wei
    Louie, Carrie
    D'Apuzzo, Massimo
    Gu, Dongqing
    Yew, Hooi
    Portnow, Jana
    Badie, Benham
    Pillai, Raju
    Aoun, Patricia
    Telatar, Milhan
    Afkhami, Michelle
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1600 - 1600
  • [47] ANALYTICAL COMPARISON OF A PD-L1 22C3 ANTIBODY LABORATORY-DEVELOPED TEST PROTOCOL ON THE BENCHMARK XT AND PD-L1 IHC 22C3 PHARMDX: PAN-TUMOR AND TRIPLE-NEGATIVE BREAST CANCER SAMPLES
    Vainer, Gilad
    Zatara, Ghadeer
    Huang, Lingkang
    Nuti, Shanthy
    Nuti, Shanthy
    Emancipator, Kenneth
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A7 - A7
  • [48] Real-world utilization of PD-L1 IHC testing and results across multiple tumor types
    Krigsfeld, Gabriel S.
    Prince, Emily
    Zerba, Kim
    Chizhevsky, Vladislav
    Ragheb, Josette William
    White, James
    CANCER RESEARCH, 2019, 79 (13)
  • [49] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [50] Analysis of real-world PD-L1 IHC testing for clinical use in patients across multiple tumor types.
    Krigsfeld, Gabriel S.
    Prince, Emily
    Zerba, Kim
    Chizhevsky, Vladislav
    Ragheb, Josette William
    White, James William
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
12345